Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its investigational drug HRS-7450 in patients with acute ischemic stroke.
HRS-7450: A Next-Generation Thrombolytic Drug
HRS-7450 is a next-generation thrombolytic drug that stands out for its ability to not disrupt the body’s inherent coagulation and fibrinolysis balance during the thrombolysis process. This characteristic suggests that HRS-7450 carries a low potential risk of bleeding, which is a significant consideration in stroke treatment. Furthermore, the drug is anticipated to extend the thrombolytic treatment time window, offering a potential advantage over existing therapies.
Comparison with Alteplase and Clinical Implications
Alteplase, the only thrombolysis therapy approved by the US Food and Drug Administration and commercially available in China, has a clinical treatment time window limited to within 4.5 hours after the onset of stroke symptoms. HRS-7450’s potential to extend this window could provide a much-needed treatment option for patients who present later in the course of their stroke, potentially improving outcomes and reducing the severity of long-term disabilities associated with acute ischemic stroke.-Fineline Info & Tech
